I'm LongbridgeAI, I can summarize articles.Illumina fell 1.74% this week to close at $215.59, underperforming the S&P 500, which rose 0.49%, by about 2.23 percentage points. The stock ran up early, touched a weekly high of $231.81 on Thursday, then pulled back sharply on Friday to end at $215.59, giving back most of the week’s gains. Weekly range was roughly 9%.
The Week
Illumina fell 1.74% this week to close at $215.59, underperforming the S&P 500, which rose 0.49%, by about 2.23 percentage points. The stock ran up early, touched a weekly high of $231.81 on Thursday, then pulled back sharply on Friday to end at $215.59, giving back most of the week’s gains. Weekly range was roughly 9%.
Key Events
The week’s institutional position changes came mostly on Monday and Thursday. B. Metzler seel. Sohn & Co. disclosed a purchase of about $982,000, Patient Capital Management bought 345,314 shares, and Proficio Capital Partners invested around $941,000. On Thursday Illumina rose 1% to a 52-week high, with attention focused on an earnings beat and upgrades. On Friday director Keith Meister disposed of about $76.95 million in common shares. There were no material company-level filings during the week.
Analyst Ratings
Of 20 institutions covering Illumina, 6 rate it buy, 4 rate it overweight, 6 rate it hold, 3 rate it underweight, and 1 rates it sell. That means 10 give buy or overweight and 4 give underweight or sell. The consensus rating is buy, with a consensus target of $198.89, about 7.7% below the current price. Targets range widely from $113.00 to $230.00. Within the life sciences tools and services industry, Illumina ranks 7th out of 53 companies.
The Week Ahead
Next week brings a busy macro calendar: Dallas Fed manufacturing activity on Monday, S&P Global manufacturing PMI final, ISM manufacturing PMI, and JOLTS job openings on Tuesday, followed by ADP private payrolls, factory orders, and EIA crude inventories on Wednesday. For Illumina, the main question is whether the stock can stabilise near its 52-week high after this week’s pullback, and how macro data shape risk appetite.
In Short
Illumina touched a 52-week high early in the week, then reversed to finish lower and trail the broader market. Ratings skew positive in count terms, but the consensus target sits below spot, suggesting the stock has already run past most brokers’ central estimates. Latest-day fund flow shows large-lot money as net seller while small and medium lots stay net buyers, pointing to a split in positioning. The near-term focus is whether price can hold near the high and how next week’s macro releases affect sentiment.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.